inolimomab (Pending FDA Approval)

Brand and Other Names:Leukotac
  • Print

Dosing & Uses

Graft vs Host Disease

Pending FDA approval for steroid-refractory acute graft-versus-host disease (aGvHD) grade II-IV

Next:

Pharmacology

Mechanism of Action

Monoclonal antibody that targets interleukin-2 receptor (IL-2), a cytokine that contributes to the development and proliferation of some WBCs including T-cells responsible for aGvHD

By linking specifically to the alpha-chain of the CD25 receptor, inolimomab prevents IL-2 from binding on the surface of the donor’s over-active T-cells which blocks their multiplication

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.